CD103-Expressing Cell Qualitative Testing Reagent
Vietnam·Risk Class TTBYT Loại C·BD CD103 (Ber-ACT8) FITC·Becton, Dickinson and Company, BD Biosciences·Registered Feb 04, 2024- Analysis ID
- 2400154ĐKLH/BYT-HTTB
- Submission ID
- 000.00.04.G18-220616-0018
- Product Type
- BD CD103 (Ber-ACT8) FITC
- Product Code
- 333155
- Manufacturer
- Becton, Dickinson and Company, BD Biosciences
- Manufacturer Country
- Theo theo phụ lục
- Product Owner
- Becton, Dickinson and Company, BD Biosciences
- Authorized Representative
- VĂN PHÒNG ĐẠI DIỆN BECTON DICKINSON ASIA LIMITED TẠI THÀNH PHỐ HỒ CHÍ MINH
- Intended Use
- CD103 (Ber-ACT8) is used for in vitro diagnosis to determine the cells expressing the CD103 antigen in peripheral blood, using the BD FACSLyric™ flow cytometry system. Clinical Applications: Expression of the CD103 antigen in the characteristic description of individuals with or suspected of having acute blood cancer. CD103 (Ber-ACT8) is a qualitative test reagent intended for use only in laboratories.
- Registration Date
- Feb 04, 2024
Access comprehensive regulatory information for CD103-Expressing Cell Qualitative Testing Reagent in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2400154ĐKLH/BYT-HTTB and manufactured by Becton, Dickinson and Company, BD Biosciences. The authorized representative in Vietnam is VĂN PHÒNG ĐẠI DIỆN BECTON DICKINSON ASIA LIMITED TẠI THÀNH PHỐ HỒ CHÍ MINH.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.